Designer probiotics: A potential therapeutic for Clostridium difficile?

Journal of Medical Microbiology

Volumn 57, Issue 6, 2008, Pages 793-794

  Sleator, Roy D ^a   Hill, Colin ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIOCIN; CEPHALOSPORIN DERIVATIVE; CHOLERA TOXIN; ESCHERICHIA COLI ENTEROTOXIN; LANTIBIOTIC; METRONIDAZOLE; PROBIOTIC AGENT; SHIGA TOXIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; COLONY FORMING UNIT; DEMOGRAPHY; DRUG DESIGN; ESCHERICHIA COLI; GASTROENTERITIS; HEALTH PROMOTION; HOSPITAL INFECTION; HUMAN; INFECTION RISK; INFECTIOUS DIARRHEA; LACTOBACILLUS SALIVARIUS; LACTOCOCCUS LACTIS; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROFLORA; NONHUMAN; NURSING HOME; PRIORITY JOURNAL; RIBOTYPING; RISK FACTOR; STOMACH PH;

AGED; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; MIDDLE AGED; PROBIOTICS; UNITED STATES;

EID: 45249108415     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.47697-0     Document Type: Letter

References (16)

1. Corr, S. C., Li, Y., Riedel, C. U., O'Toole, P. W., Hill, C. & Gahan, C. G. (2007). Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci U S A 104, 7617-7621.
2. Crogan, N. L. & Evans, B. C. (2007). Clostridium difficile: an emerging epidemic in nursing homes. Geriatr Nurs 28, 161-164.
3. Gardiner, G. E., Rea, M. C., O' Riordan, B., O' Connor, P., Morgan, S. M., Lawlor, P. G., Lynch, P. B., Cronin, M., Ross, R. P. & Hill, C. (2007). Fate of the two-component lantibiotic lacticin 3147 in the gastrointestinal tract. Appl Environ Microbiol 73, 7103-7109.
4. Hickson, M., D'Souza, A. L., Muthu, N., Rogers, T. R., Want, S., Rajkumar, C. & Bulpitt, C. J. (2007). Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335, 80.
5. Kuijper, E. J., van Dissel, J. T. & Wilcox, M. H. (2007). Clostridium difficile, changing epidemiology and new treatment options. Curr Opin Infect Dis 20, 376-383.
6. McFarland, L. V. (2005). Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 54, 101-111.
7. Paton, A. W., Morona, R. & Paton, J. C. (2000). A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 6, 265-270.
8. Paton, A. W., Morona, R. & Paton, J. C. (2006). Designer probiotics for prevention of enteric infections. Nat Rev Microbiol 4, 193-200.
9. Rea, M. C., Clayton, E., O'Connor, P. M., Shanahan, F., Kiely, B., Ross, R. P. & Hill, C. (2007). Antimicrobial activity of lacticin 3147 against clinical Clostridium difficile strains. J Med Microbiol 56, 940-946.
10. Sheehan, V. M., Sleator, R. D., Fitzgerald, G. F. & Hill, C. (2006). Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of Lactobacillus salivarius UCC118. Appl Environ Microbiol 72, 2170-2177.
11. Sheehan, V. M., Sleator, R. D., Hill, C. & Fitzgerald, G. F. (2007). Improving gastric transit, gastrointestinal persistence and therapeutic efficacy of the probiotic strain Bifidobacterium breve UCC2003. Microbiology 153, 3563-3571.
12. Sleator, R. D. & Hill, C. (2006). Patho-biotechnology: using bad bugs to do good things. Curr Opin Biotechnol 17, 211-216.
13. Sleator, R. D. & Hill, C. (2007a). Improving probiotic function using a patho-biotechnology approach. Gene Ther Mol Biol 11, 269-274.
14. Sleator, R. D. & Hill, C. (2007b). Patho-biotechnology; using bad bugs to make good bugs better. Sci Prog 90, 1-14.
15. Sleator, R. D. & Hill, C. (2007c). Probiotics as therapeutics for the developing world. J Infect Developing Countries 1, 7-12.
16. Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E. & McDonald, L. C. (2005). Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366, 1079-1084.